Objectives Nerve growth factor (NGF) has emerged as a key driver of pain in osteoarthritis (OA) and antibodies to NGF are potent analgesics in human disease. Here, we validate a novel vaccine strategy to generate anti-NGF antibodies for reversal of pain behaviour in a surgical model of OA.
Methods Virus-like particles were derived from the cucumber mosaic virus (CuMV) and coupled to expressed recombinant NGF to create the vaccine. 10-week-old male m...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's Version
- BMJ Publishing Group Publisher's website
- Annals of the Rheumatic Diseases Journal website
- Publication date:
- Acceptance date:
- Pubs id:
- Local pid:
- Copyright holder:
- von Loga et al.
- Copyright date:
- This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made.
Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis
If you are the owner of this record, you can report an update to it here: Report update to this record